Réactivité à la dose faible de rituximab dans la myasthénie grave grave généralisée réfractaire.

Verrouillé
Avatar du membre

Auteur du sujet
Pboulanger Prés.
Administrateur
Administrateur
Messages : 10762
Enregistré le : 02 févr. 2010 18:41
14
Localisation  : La Chapelle en Serval F-60520
Genre :
Zodiaque :
Âge : 67
    Windows 10 Firefox

Réactivité à la dose faible de rituximab dans la myasthénie grave grave généralisée réfractaire.

Message par Pboulanger Prés. »

:hi:

:arrow: Lu sur :

[ligne][/ligne]

Traduction disponible directement en cliquant en bas à droite de ce message sur notre forum

Image

[ligne][/ligne]

Responsiveness to low-dose rituximab in refractory generalized myasthenia gravis.
Jing S1, Song Y2, Song J3, Pang S4, Quan C3, Zhou L3, Huang Y3, Lu J3, Xi J5, Zhao C6.
J Neuroimmunol. 2017 May 30. pii: S0165-5728(17)30074-7. doi: 10.1016/j.jneuroim.2017.05.021.

Abstract

We aim to investigate the effect of a low dose of rituximab (RTX) in improving the clinical symptoms of refractory generalized myasthenia gravis (MG).

Eight patients with refractory generalized MG were treated with a low dose of 600mg RTX. Patients were evaluated by serial clinical scales, flow cytometry of peripheral blood B, T and NK cells, immunoglobulin, complement levels and antibody titer.

The quantitative MG score (QMGS), manual muscle testing (MMT), MG-related activities of daily living (MG-ADL) and MG-specific quality-of-life (QOL) were recorded at baseline as well as 1, 3, and 6months after RTX infusion.

The initial improvement was recorded at 1month after treatment. QMGS, MMT and MG-ADL were significantly improved and the average steroid dosage reduction was 43% (p=0.018) at 6months.
600mg RTX was sufficient to deplete B cells and maintain low B-cell counts until 6months after infusion. Treatment with RTX did not result in a significant change in the percentage of CD4+, CD8+ T-cells while an average increase in the percentage of NK cells.

Our study found successful B cell depletion was parallel to symptoms remission and change in serum C3 and C4 levels. Serum AChR antibody levels were independent of clinical response and not influenced by RTX.

Therefore, low dose of 600mg RTX may be sufficient in depleting B cells, maintaining low B-cell counts and improving the clinical symptoms of MG in 6months.


Message d' un membre de l'équipe technique
Nous utilisons un service automatique de traduction fourni par YANDEX.
Soyez vigilant sur le risque de contre-sens inhérent à ce genre d'outils.
Amicalement,
Image
Verrouillé

Retourner vers « 2017 »